June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Controlled Release of a Rho Kinase (ROCK)-Selective Inhibitor with Polylactic Acid Microspheres
Author Affiliations & Notes
  • Sho Koda
    Biomedical Engineering, Doshisha University, Kyotanabe, Japan
    Biomaterials, Kyoto University, Kyoto, Japan
  • Takashi Saito
    Biomaterials, Kyoto University, Kyoto, Japan
  • Junji Kitano
    Biomedical Engineering, Doshisha University, Kyotanabe, Japan
  • Naoki Okumura
    Biomedical Engineering, Doshisha University, Kyotanabe, Japan
    Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto, Japan
  • Shigeru Kinoshita
    Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto, Japan
  • Yasuhiko Tabata
    Biomaterials, Kyoto University, Kyoto, Japan
  • Noriko Koizumi
    Biomedical Engineering, Doshisha University, Kyotanabe, Japan
    Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto, Japan
  • Footnotes
    Commercial Relationships Sho Koda, None; Takashi Saito, None; Junji Kitano, None; Naoki Okumura, None; Shigeru Kinoshita, Senju Pharmaceutical Co (P), Santen Pharmaceutical Co (P), Otsuka Pharmaceutical Co (C), Alcon (R), AMO (R), HOYA (R); Yasuhiko Tabata, None; Noriko Koizumi, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 1689. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Sho Koda, Takashi Saito, Junji Kitano, Naoki Okumura, Shigeru Kinoshita, Yasuhiko Tabata, Noriko Koizumi; Controlled Release of a Rho Kinase (ROCK)-Selective Inhibitor with Polylactic Acid Microspheres. Invest. Ophthalmol. Vis. Sci. 2013;54(15):1689.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: We previously reported that the Rho kinase (ROCK) inhibitor Y-27632 promoted the wound healing of corneal endothelial cells in a primate model. Thus, Y-27632 shows promise as a drug that can be used for the clinical treatment of corneal endothelial defects. The purpose of this present study was to design polylactic acid (PLA) microspheres that can be used for the controlled release of Y-27632 in the anterior chamber.

Methods: PLA microspheres incorporating Y-27632 (Y-27632-PLA) were prepared via a double-emulsion [(water in oil) in water] solvent evaporation method. The in vitro release test of Y-27632-PLA was performed in a phosphate-buffered solution (pH7.4) at 37°C.The amount of Y-27632 released was determined by use of high-performance liquid chromatography (HPLC). To evaluate the toxicity of PLA microspheres without Y-27632 after they were injected into the anterior chamber of rabbit eyes, slit-lamp examinations, and corneal thickness and intraocular pressure measurements were performed up to14 days after injection, followed by immunohistochemical analysis.

Results: Y-27632 was released from PLA microspheres over 28 days. The percent of Y-27632 released was 70.0, 77.9, and 98.2% at 7, 14, and 28 days, respectively. The release pattern of Y-27632 could be changed by altering the molecular weight of the PLA that was used. In all eyes injected with the PLA microspheres, normal corneal thickness was observed, with no inflammation or elevation of intraocular pressure. The corneal endothelial cell density and the expression of functional protein were found to be normal.

Conclusions: The findings of this study demonstrate that PLA microspheres are promising candidates for the controlled release of Y-27632. The Y-27632-PLA is applicable as a pharmaceutical agent for the treatment of corneal endothelial dysfunction.

Keywords: 481 cornea: endothelium • 480 cornea: basic science • 561 injection  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×